Further data from the TRANSCEND NHL 001 study supporting the role of CART therapy in mantle cell lymphoma. However it appears the rate of toxicity is just a little higher than in the DLBCL indication. Is this related to burden of disease and disease distribution ? |
Log In with AHPRA